Extended Data Fig. 2: Comparison of GLP-1GIP:Tesa vs. GLP-1:GIP:Lani.
From: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
a,b, Dose-response curves of ligand-induced BRET changes between Nluc-tagged Gαs recruitment to GFP-tagged GLP-1R or GIPR. a, HEK293T cells expressing GLP-1R (n = 3 independent biological replicates per group). b, HEK293T cells expressing GIPR (n = 6 independent biological replicates per group). c–e, DIO mice were treated once-daily via s.c. injections of GLP-1:Lani, GLP-1:GIP:Lani or vehicle for 14 days. 10 nmol kg−1. c, Homeostatic model assessment of insulin resistance (HOMA-IR) (n = 7 Vhcl, n = 6 GLP-1:Lani, n = 8 GLP-1:GIP:Lani). d, Fasting blood glucose (n = 8 Vhcl, n = 7 GLP-1:Lani, n = 8 GLP-1:GIP:Lani). e, Fasting plasma insulin (Vhcl, n = 7; GLP-1:Lani, n = 6; GLP-1:GIP:Lani, n = 8). f–h, DIO mice were treated once-daily via s.c. injections of GLP-1:Tesa, GLP-1:GIP:Tesa, GLP-1:Lani, GLP-1:GIP:Lani or vehicle for 14 days. GLP-1:Lani, n = 7; all other groups, n = 8. 10 nmol kg−1. f, placebo-corrected effects on body weight. g, placebo-corrected effects on fat mass. h, placebo-corrected effects on fasting blood glucose. Data were analysed using one-way ANOVA with Bonferroni post hoc multiple-comparison test (c–h). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. Exact P-values, n-values and detailed statistics are provided in Supplementary Tables 1 and 3 and the Data Source File.
